



## **Akebia Therapeutics to Present at Upcoming Investor Conference**

May 15, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2018-- [Akebia Therapeutics](http://www.akebia.com), Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will present at the UBS Global Healthcare Conference on Tuesday, May 22, 2018, at 4:00 p.m. Eastern Time, at the Grand Hyatt New York in New York City.

A live webcast of the presentation will be available on the company's website at [www.akebia.com](http://www.akebia.com). To access the webcast, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akebia's website following the conference.

### **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at [www.akebia.com](http://www.akebia.com), which does not form a part of this release.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180515005100/en/>

Source: Akebia Therapeutics, Inc.

### **Akebia Therapeutics**

John Garabo, 617-844-6130  
Director, Corporate Communications  
[jgarabo@akebia.com](mailto:jgarabo@akebia.com)